The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...

In this Science segment, we examine the European Medicines Agency's recent decision to recommend granting marketing ...

Our Director of Research Dr Sheona Scales describes her four highlights from this year's Clinical Trials on Alzheimer's ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Today, the first monoclonal antibodies, lecanemab and donanemab, are available, showing that their reduction effect on these ...

The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at ...

The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

A new Alzheimer’s test collects just a few drops of blood from a finger prick, which can be mailed to a lab for analysis.

Lecanemab, a drug designed to slow the progression of early stage Alzheimer's will not be available to patients in Sweden for ...

Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...

A preprint research letter linking the Alzheimer's drug lecanemab (Leqembi) with excess deaths was withdrawn last week. The ...

Eisai (ESAIY) and Biogen (BIIB) announced that a positive opinion has been received from the Committee for Medicinal Products for Human Use of ...